Alpha 2.0
Login Register
» Articles » PMID: 35451363

Vaccine-induced and Naturally-acquired Protection Against Omicron and Delta Symptomatic Infection and Severe COVID-19 Outcomes, France, December 2021 to January 2022

Overview
Journal Euro Surveill
Specialty Infectious Diseases
Date 2022 Apr 22
PMID 35451363
Authors
Milena Suarez Castillo
Hamid Khaoua
Noemie Courtejoie
Affiliations
Soon will be listed here.
Abstract

We assessed the protection conferred by naturally-acquired, vaccine-induced and hybrid immunity during the concomitant Omicron and Delta epidemic waves in France on symptomatic infection and severe COVID-19. The greatest levels of protection against both variants were provided by hybrid immunity. Protection against Omicron symptomatic infections was systematically lower and waned at higher speed than against Delta in those vaccinated. In contrast, there were little differences in variant-specific protection against severe inpatient outcomes in symptomatic individuals.

Citing Articles

Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024.

Zhou G, Dael N, Verweij S, Balafas S, Mubarik S, Oude Rengerink K Eur Respir Rev. 2025; 34(175).

PMID: 39971395 PMC: 11836669. DOI: 10.1183/16000617.0222-2024.

Comparative Evolutionary Epidemiology of SARS-CoV-2 Delta and Omicron Variants in Kuwait.

Alkhamis M, Hussain A, Al-Therban F Viruses. 2025; 16(12.

PMID: 39772182 PMC: 11680180. DOI: 10.3390/v16121872.

Planning and adjusting the COVID-19 booster vaccination campaign to reduce disease burden.

Di Domenico L, Goldberg Y, Colizza V Infect Dis Model. 2024; 10(1):150-162.

PMID: 39380724 PMC: 11459620. DOI: 10.1016/j.idm.2024.09.002.

Pediatric antibody responses to SARS-CoV-2 after infection and vaccination in Calgary, Canada.

Ricketson L, Doucette E, Alatorre I, Tarannum T, Gray J, Booth W BMC Infect Dis. 2024; 24(1):705.

PMID: 39026179 PMC: 11256562. DOI: 10.1186/s12879-024-09615-3.

Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination.

Walmsley S, Nabipoor M, Qi F, Lovblom L, Ravindran R, Colwill K Vaccines (Basel). 2024; 12(6).

PMID: 38932293 PMC: 11209254. DOI: 10.3390/vaccines12060564.

References
1.
Tseng H, Ackerson B, Luo Y, Sy L, Talarico C, Tian Y . Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022; 28(5):1063-1071. PMC: 9117141. DOI: 10.1038/s41591-022-01753-y. View
2.
Kahn F, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M . Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022. Euro Surveill. 2022; 27(9). PMC: 8895467. DOI: 10.2807/1560-7917.ES.2022.27.9.2200121. View
3.
Auvigne V, Vaux S, Le Strat Y, Schaeffer J, Fournier L, Tamandjou C . Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021-January 2022: A retrospective, population-based, matched cohort study. EClinicalMedicine. 2022; 48:101455. PMC: 9121907. DOI: 10.1016/j.eclinm.2022.101455. View
4.
Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E . Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022; 386(16):1532-1546. PMC: 8908811. DOI: 10.1056/NEJMoa2119451. View
5.
Jackson M, Nelson J . The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013; 31(17):2165-8. DOI: 10.1016/j.vaccine.2013.02.053. View